{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T02:57:52Z","timestamp":1780369072056,"version":"3.54.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T00:00:00Z","timestamp":1663804800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T00:00:00Z","timestamp":1663804800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Deutsches Krebsforschungszentrum (DKFZ)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Imaging"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Aim<\/jats:title>\n                <jats:p>To compare [<jats:sup>68<\/jats:sup>Ga]PSMA-11 PET-CT, [<jats:sup>68<\/jats:sup>Ga]PSMA-11 PET-MRI and MRI in a cohort of prostate cancer (PCa) patients in biochemical recurrence after initial curative therapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Materials and methods<\/jats:title>\n                <jats:p>Fifty-three patients with biochemically recurrent PCa underwent whole-body [<jats:sup>68<\/jats:sup>Ga]PSMA-11 PET-CT 1\u2009hour post-injection (p.i.) followed by [<jats:sup>68<\/jats:sup>Ga]PSMA-11 PET-MRI 2.5\u2009hours p.i., including a multiparametric MRI pelvic protocol examination. Imaging data analysis consisted of visual (qualitative) evaluation of the PET-CT, PET-MRI and MRI scans, as well as semi-quantitative and quantitative analyses of the PET and MRI data, including calculation of the parameters standardized uptake value (SUV) and apparent diffusion coefficient (ADC) derived from the PCa lesions. Association analysis was performed between imaging and clinical data, including PSA level and Gleason score. The results were considered significant for <jats:italic>p<\/jats:italic>-values less than 0.05 (<jats:italic>p<\/jats:italic>\u00a0&lt;\u20090.05).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The hybrid imaging modalities [<jats:sup>68<\/jats:sup>Ga]PSMA-11 PET-CT and PET-MRI were positive in more patients than MRI alone. In particular, PET-CT detected lesions suggestive of PCa relapse in 34\/53 (64.2%), PET-MRI in 36\/53 (67.9%) and MRI in 23\/53 patients (43.4%). While no significant differences in lesion detection rate were observed between PET-CT and PET-MRI, the latter was particularly efficient in detection of local recurrences in the prostate bed mainly due to the contribution of the MRI part of the modality. Association analysis revealed a statistically significant increase in the probability of a positive scan with increasing PSA levels for all imaging modalities. Accordingly, there was no significant association between scan positivity rate and Gleason score for any imaging modality. No significant correlation was observed between SUV and ADC values in lymph node metastases.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>[<jats:sup>68<\/jats:sup>Ga]PSMA-11 PET-CT and PET-MRI provide equally good detection rates for PCa recurrence, both outperforming stand-alone MRI.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40644-022-00489-9","type":"journal-article","created":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T23:03:41Z","timestamp":1663887821000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Hybrid imaging with [68Ga]PSMA-11 PET-CT and PET-MRI in biochemically recurrent prostate cancer"],"prefix":"10.1186","volume":"22","author":[{"given":"P. A.","family":"Glemser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. T.","family":"Rotkopf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. H.","family":"Ziener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Beuthien-Baumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Weru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Kopp-Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. P.","family":"Schlemmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Dimitrakopoulou-Strauss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8739-8741","authenticated-orcid":false,"given":"C.","family":"Sachpekidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,22]]},"reference":[{"issue":"4","key":"489_CR1","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.eururo.2016.08.002","volume":"71","author":"P Cornford","year":"2017","unstructured":"Cornford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol. 2017;71(4):630\u201342. https:\/\/doi.org\/10.1016\/j.eururo.2016.08.002 Epub 2016 Aug 31. PMID: 27591931.","journal-title":"Eur Urol"},{"issue":"2","key":"489_CR2","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.eururo.2020.09.046","volume":"79","author":"P Cornford","year":"2021","unstructured":"Cornford P, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II-2020 update: treatment of relapsing and metastatic prostate cancer. Eur Urol. 2021;79(2):263\u201382. https:\/\/doi.org\/10.1016\/j.eururo.2020.09.046 Epub 2020 Oct 7. PMID: 33039206.","journal-title":"Eur Urol"},{"issue":"4","key":"489_CR3","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1001\/jama.294.4.433","volume":"294","author":"SJ Freedland","year":"2005","unstructured":"Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA. 2005;294(4):433\u20139. https:\/\/doi.org\/10.1001\/jama.294.4.433 PMID: 16046649.","journal-title":"JAMA"},{"issue":"3","key":"489_CR4","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.urology.2006.03.075","volume":"68","author":"PA Kupelian","year":"2006","unstructured":"Kupelian PA, Mahadevan A, Reddy CA, Reuther AM, Klein EA. Use of different definitions of biochemical failure after external beam radiotherapy changes conclusions about relative treatment efficacy for localized prostate cancer. Urology. 2006;68(3):593\u20138. https:\/\/doi.org\/10.1016\/j.urology.2006.03.075 Epub 2006 Sep 18. PMID: 16979731.","journal-title":"Urology"},{"issue":"6","key":"489_CR5","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1002\/cncr.23293","volume":"112","author":"N Suardi","year":"2008","unstructured":"Suardi N, Porter CR, Reuther AM, Walz J, Kodama K, Gibbons RP, et al. A nomogram predicting long-term biochemical recurrence after radical prostatectomy. Cancer. 2008;112(6):1254\u201363. https:\/\/doi.org\/10.1002\/cncr.23293 PMID: 18286530.","journal-title":"Cancer"},{"issue":"5","key":"489_CR6","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/j.euf.2016.11.002","volume":"4","author":"FE von Eyben","year":"2018","unstructured":"von Eyben FE, Picchio M, von Eyben R, Rhee H, Bauman G. 68Ga-labeled prostate-specific membrane antigen ligand positron emission tomography\/computed tomography for prostate cancer: a systematic review and meta-analysis. Eur Urol Focus. 2018;4(5):686\u201393. https:\/\/doi.org\/10.1016\/j.euf.2016.11.002 Epub 2016 Nov 15. PMID: 28753806.","journal-title":"Eur Urol Focus"},{"key":"489_CR7","doi-asserted-by":"publisher","unstructured":"Das JP, Woo S. Multiparametric prostate MRI for biochemical failure in the era of targeted PET radiotracers: point-MRI may no longer be needed in patient workup. AJR Am J Roentgenol. 2022. https:\/\/doi.org\/10.2214\/AJR.22.27882 Epub ahead of print. PMID: 35642763.","DOI":"10.2214\/AJR.22.27882"},{"issue":"6","key":"489_CR8","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.2214\/AJR.19.21905","volume":"214","author":"P Bhargava","year":"2020","unstructured":"Bhargava P, Ravizzini G, Chapin BF, Kundra V. Imaging biochemical recurrence after prostatectomy: where are we headed? AJR Am J Roentgenol. 2020;214(6):1248\u201358. https:\/\/doi.org\/10.2214\/AJR.19.21905 Epub 2020 Mar 4. PMID: 32130049.","journal-title":"AJR Am J Roentgenol"},{"issue":"8","key":"489_CR9","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1007\/s00259-017-3711-7","volume":"44","author":"A Afshar-Oromieh","year":"2017","unstructured":"Afshar-Oromieh A, Holland-Letz T, Giesel FL, Kratochwil C, Mier W, Haufe S, et al. Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET\/CT in patients with recurrent prostate cancer: evaluation in 1007 patients. Eur J Nucl Med Mol Imaging. 2017;44(8):1258\u201368. https:\/\/doi.org\/10.1007\/s00259-017-3711-7 Epub 2017 May 12. Erratum in: Eur J Nucl Med Mol Imaging. 2017 Sep;44(10):1781. PMID: 28497198; PMCID: PMC5486817.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"489_CR10","doi-asserted-by":"publisher","first-page":"668","DOI":"10.2967\/jnumed.115.154153","volume":"56","author":"M Eiber","year":"2015","unstructured":"Eiber M, Maurer T, Souvatzoglou M, Beer AJ, Ruffani A, Haller B, et al. Evaluation of hybrid 68Ga-PSMA ligand PET\/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med. 2015;56(5):668\u201374. https:\/\/doi.org\/10.2967\/jnumed.115.154153 Epub 2015 Mar 19. Erratum in: J Nucl Med. 2016 Aug;57(8):1325. PMID: 25791990.","journal-title":"J Nucl Med"},{"issue":"13","key":"489_CR11","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1002\/pros.23869","volume":"79","author":"C Rousseau","year":"2019","unstructured":"Rousseau C, Le Thiec M, Ferrer L, Rusu D, Rauscher A, Maucherat B, et al. Preliminary results of a 68 Ga-PSMA PET\/CT prospective study in prostate cancer patients with occult recurrence: diagnostic performance and impact on therapeutic decision-making. Prostate. 2019;79(13):1514\u201322. https:\/\/doi.org\/10.1002\/pros.23869 Epub 2019 Aug 17. PMID: 31421657.","journal-title":"Prostate"},{"issue":"9","key":"489_CR12","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1016\/S1470-2045(19)30415-2","volume":"20","author":"J Calais","year":"2019","unstructured":"Calais J, Ceci F, Eiber M, Hope TA, Hofman MS, Rischpler C, et al. 18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial. Lancet Oncol. 2019;20(9):1286\u201394. https:\/\/doi.org\/10.1016\/S1470-2045(19)30415-2 Epub 2019 Jul 30. Erratum in: Lancet Oncol. 2019 Nov;20(11):e613. Erratum in: Lancet Oncol. 2020 Jun;21(6):e304. PMID: 31375469; PMCID: PMC7469487.","journal-title":"Lancet Oncol"},{"issue":"5","key":"489_CR13","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1007\/s00259-016-3594-z","volume":"44","author":"MT Freitag","year":"2017","unstructured":"Freitag MT, Radtke JP, Afshar-Oromieh A, Roethke MC, Hadaschik BA, Gleave M, et al. Local recurrence of prostate cancer after radical prostatectomy is at risk to be missed in 68Ga-PSMA-11-PET of PET\/CT and PET\/MRI: comparison with mpMRI integrated in simultaneous PET\/MRI. Eur J Nucl Med Mol Imaging. 2017;44(5):776\u201387. https:\/\/doi.org\/10.1007\/s00259-016-3594-z Epub 2016 Dec 17. PMID: 27988802.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"489_CR14","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s00259-016-3578-z","volume":"44","author":"C Uprimny","year":"2017","unstructured":"Uprimny C, Kroiss AS, Decristoforo C, Fritz J, Warwitz B, Scarpa L, et al. Early dynamic imaging in 68Ga- PSMA-11 PET\/CT allows discrimination of urinary bladder activity and prostate cancer lesions. Eur J Nucl Med Mol Imaging. 2017;44(5):765\u201375. https:\/\/doi.org\/10.1007\/s00259-016-3578-z Epub 2016 Nov 29. PMID: 27900519.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"10","key":"489_CR15","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1007\/s00259-017-3743-z","volume":"44","author":"C Uprimny","year":"2017","unstructured":"Uprimny C, Kroiss AS, Fritz J, Decristoforo C, Kendler D, von Guggenberg E, et al. Early PET imaging with [68]Ga-PSMA-11 increases the detection rate of local recurrence in prostate cancer patients with biochemical recurrence. Eur J Nucl Med Mol Imaging. 2017;44(10):1647\u201355. https:\/\/doi.org\/10.1007\/s00259-017-3743-z Epub 2017 Jun 6. PMID: 28589253.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"489_CR16","first-page":"351","volume":"8","author":"C Sachpekidis","year":"2018","unstructured":"Sachpekidis C, Pan L, Hadaschik BA, Kopka K, Haberkorn U, Dimitrakopoulou-Strauss A. 68Ga-PSMA-11 PET\/CT in prostate cancer local recurrence: impact of early images and parametric analysis. Am J Nucl Med Mol Imaging. 2018;8(5):351\u20139 PMID: 30510852; PMCID: PMC6261880.","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"489_CR17","doi-asserted-by":"publisher","unstructured":"Strauss DS, Sachpekidis C, Kopka K, Pan L, Haberkorn U, Dimitrakopoulou-Strauss A. Pharmacokinetic studies of [68 Ga]Ga-PSMA-11 in patients with biochemical recurrence of prostate cancer: detection, differences in temporal distribution and kinetic modelling by tissue type. Eur J Nucl Med Mol Imaging. 2021. https:\/\/doi.org\/10.1007\/s00259-021-05420-1 Epub ahead of print. PMID: 34110436.","DOI":"10.1007\/s00259-021-05420-1"},{"issue":"3","key":"489_CR18","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1007\/s00259-019-04548-5","volume":"47","author":"F Haupt","year":"2020","unstructured":"Haupt F, Dijkstra L, Alberts I, Sachpekidis C, Fech V, Boxler S, et al. 68Ga-PSMA-11 PET\/CT in patients with recurrent prostate cancer-a modified protocol compared with the common protocol. Eur J Nucl Med Mol Imaging. 2020;47(3):624\u201331. https:\/\/doi.org\/10.1007\/s00259-019-04548-5 Epub 2019 Nov 1. PMID: 31673789.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"489_CR19","doi-asserted-by":"publisher","unstructured":"Uprimny C, Bayerschmidt S, Kroiss AS, Fritz J, Nilica B, Svirydenka H, et al. Early injection of furosemide increases detection rate of local recurrence in prostate cancer patients with biochemical recurrence referred for 68Ga-PSMA-11 PET\/CT. J Nucl Med. 2021:jnumed.120.261866. https:\/\/doi.org\/10.2967\/jnumed.120.261866 Epub ahead of print. PMID: 33712533.","DOI":"10.2967\/jnumed.120.261866"},{"issue":"9","key":"489_CR20","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.2967\/jnumed.120.257741","volume":"62","author":"I Alberts","year":"2021","unstructured":"Alberts I, Niklas-H\u00fcnermund J, Sachpekidis C, Zacho HD, Mingels C, Dijkstra L, et al. Combination of forced diuresis with additional late imaging in 68Ga-PSMA-11 PET\/CT: effects on lesion visibility and radiotracer uptake. J Nucl Med. 2021;62(9):1252\u20137. https:\/\/doi.org\/10.2967\/jnumed.120.257741 Epub 2021 Feb 5. PMID: 33547214.","journal-title":"J Nucl Med"},{"issue":"8","key":"489_CR21","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1007\/s00259-018-3989-0","volume":"45","author":"K Rahbar","year":"2018","unstructured":"Rahbar K, Afshar-Oromieh A, B\u00f6gemann M, Wagner S, Sch\u00e4fers M, Stegger L, et al. 18F-PSMA-1007 PET\/CT at 60 and 120 minutes in patients with prostate cancer: biodistribution, tumour detection and activity kinetics. Eur J Nucl Med Mol Imaging. 2018;45(8):1329\u201334. https:\/\/doi.org\/10.1007\/s00259-018-3989-0 Epub 2018 Mar 14. PMID: 29541812.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"489_CR22","doi-asserted-by":"publisher","first-page":"362","DOI":"10.2967\/jnumed.118.212233","volume":"60","author":"FL Giesel","year":"2019","unstructured":"Giesel FL, Knorr K, Spohn F, Will L, Maurer T, Flechsig P, et al. Detection efficacy of 18F-PSMA-1007 PET\/CT in 251 patients with biochemical recurrence of prostate cancer after radical prostatectomy. J Nucl Med. 2019;60(3):362\u20138. https:\/\/doi.org\/10.2967\/jnumed.118.212233 Epub 2018 Jul 24. PMID: 30042163; PMCID: PMC6424235.","journal-title":"J Nucl Med"},{"issue":"5","key":"489_CR23","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1007\/s00259-013-2660-z","volume":"41","author":"A Afshar-Oromieh","year":"2014","unstructured":"Afshar-Oromieh A, Haberkorn U, Schlemmer HP, Fenchel M, Eder M, Eisenhut M, et al. Comparison of PET\/CT and PET\/MRI hybrid systems using a 68Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience. Eur J Nucl Med Mol Imaging. 2014;41(5):887\u201397. https:\/\/doi.org\/10.1007\/s00259-013-2660-z Epub 2013 Dec 19. PMID: 24352789.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"489_CR24","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/s00259-015-3206-3","volume":"43","author":"MT Freitag","year":"2016","unstructured":"Freitag MT, Radtke JP, Hadaschik BA, Kopp-Schneider A, Eder M, Kopka K, et al. Comparison of hybrid (68)Ga-PSMA PET\/MRI and (68)Ga-PSMA PET\/CT in the evaluation of lymph node and bone metastases of prostate cancer. Eur J Nucl Med Mol Imaging. 2016;43(1):70\u201383. https:\/\/doi.org\/10.1007\/s00259-015-3206-3 Epub 2015 Oct 28. PMID: 26508290.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"489_CR25","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1007\/s11307-019-01424-4","volume":"22","author":"N Guberina","year":"2020","unstructured":"Guberina N, Hetkamp P, Ruebben H, Fendler W, Grueneisen J, Suntharalingam S, et al. Whole-body integrated [68Ga]PSMA-11-PET\/MR imaging in patients with recurrent prostate cancer: comparison with whole-body PET\/CT as the standard of reference. Mol Imaging Biol. 2020;22(3):788\u201396. https:\/\/doi.org\/10.1007\/s11307-019-01424-4 PMID: 31482413.","journal-title":"Mol Imaging Biol"},{"issue":"2","key":"489_CR26","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1007\/s00330-021-08140-0","volume":"32","author":"S Jentjens","year":"2022","unstructured":"Jentjens S, Mai C, Ahmadi Bidakhvidi N, De Coster L, Mertens N, Koole M, et al. Prospective comparison of simultaneous [68Ga]Ga-PSMA-11 PET\/MR versus PET\/CT in patients with biochemically recurrent prostate cancer. Eur Radiol. 2022;32(2):901\u201311. https:\/\/doi.org\/10.1007\/s00330-021-08140-0 Epub 2021 Aug 10. PMID: 34374802.","journal-title":"Eur Radiol"},{"key":"489_CR27","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1148\/radiol.2541090361","volume":"254","author":"CJ McMahon","year":"2010","unstructured":"McMahon CJ, Rofsky NM, Pedrosa I. Lymphatic metastases from pelvic tumors: anatomic classification, characterization, and staging. Radiology. 2010;254:31\u201346.","journal-title":"Radiology"},{"issue":"7","key":"489_CR28","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1007\/s00259-019-04308-5","volume":"46","author":"LM Sawicki","year":"2019","unstructured":"Sawicki LM, Kirchner J, Buddensieck C, Antke C, Ullrich T, Schimm\u00f6ller L, et al. Prospective comparison of whole-body MRI and 68Ga-PSMA PET\/CT for the detection of biochemical recurrence of prostate cancer after radical prostatectomy. Eur J Nucl Med Mol Imaging. 2019;46(7):1542\u201350. https:\/\/doi.org\/10.1007\/s00259-019-04308-5 Epub 2019 Mar 16. PMID: 30879122.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"489_CR29","unstructured":"PMOD. Iso-contour Mode (Pseudo-Snake). Available at: http:\/\/www.pmod.com\/files\/download\/v31\/doc\/pbas\/4729.htm. Retrieved October 28, 2021."},{"issue":"3","key":"489_CR30","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1016\/j.neuroimage.2006.01.015","volume":"31","author":"PA Yushkevich","year":"2006","unstructured":"Yushkevich PA, Piven J, Hazlett HC, Smith RG, Ho S, Gee JC, et al. User-guided 3D active contour segmentation of anatomical structures: significantly improved efficiency and reliability. Neuroimage. 2006;31(3):1116\u201328. https:\/\/doi.org\/10.1016\/j.neuroimage.2006.01.015 Epub 2006 Mar 20. PMID: 16545965.","journal-title":"Neuroimage"},{"issue":"4","key":"489_CR31","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1080\/10473289.2003.10466174","volume":"53","author":"A Hamlett","year":"2003","unstructured":"Hamlett A, Ryan L, Serrano-Trespalacios P, Wolfinger R. Mixed models for assessing correlation in the presence of replication. J Air Waste Manag Assoc. 2003;53(4):442\u201350. https:\/\/doi.org\/10.1080\/10473289.2003.10466174 PMID: 12708508.","journal-title":"J Air Waste Manag Assoc"},{"key":"489_CR32","first-page":"2424","volume-title":"SAS global forum proceedings","author":"K Irimata","year":"2018","unstructured":"Irimata K, Wakim P, Li X. Estimation of correlation coefficient in data with repeated measures. In:  SAS global forum proceedings; 2018. p. 2424\u2013018."},{"key":"489_CR33","doi-asserted-by":"publisher","unstructured":"Huo H, Shen S, He D, Liu B, Yang F. Head-to-head comparison of 68Ga-PSMA-11 PET\/CT and 68Ga-PSMA-11 PET\/MRI in the detection of biochemical recurrence of prostate cancer: summary of head-to-head comparison studies. Prostate Cancer Prostatic Dis. 2022. https:\/\/doi.org\/10.1038\/s41391-022-00581-y Epub ahead of print. PMID: 35931759.","DOI":"10.1038\/s41391-022-00581-y"},{"issue":"11","key":"489_CR34","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.2967\/jnumed.116.173492","volume":"57","author":"I Rauscher","year":"2016","unstructured":"Rauscher I, Maurer T, Beer AJ, Graner FP, Haller B, Weirich G, et al. Value of 68Ga-PSMA HBED-CC PET for the assessment of lymph node metastases in prostate cancer patients with biochemical recurrence: comparison with histopathology after salvage lymphadenectomy. J Nucl Med. 2016;57(11):1713\u20139. https:\/\/doi.org\/10.2967\/jnumed.116.173492 Epub 2016 Jun 3. PMID: 27261524.","journal-title":"J Nucl Med"},{"issue":"11","key":"489_CR35","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1007\/s00259-019-04438-w","volume":"46","author":"A Afshar-Oromieh","year":"2019","unstructured":"Afshar-Oromieh A, Vollnberg B, Alberts I, B\u00e4hler A, Sachpekidis C, Dijkstra L, et al. Comparison of PSMA-ligand PET\/CT and multiparametric MRI for the detection of recurrent prostate cancer in the pelvis. Eur J Nucl Med Mol Imaging. 2019;46(11):2289\u201397. https:\/\/doi.org\/10.1007\/s00259-019-04438-w Epub 2019 Jul 27. PMID: 31350604.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"489_CR36","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1007\/s00259-018-4058-4","volume":"45","author":"HD Zacho","year":"2018","unstructured":"Zacho HD, Nielsen JB, Afshar-Oromieh A, Haberkorn U, deSouza N, De Paepe K, et al. Prospective comparison of 68Ga-PSMA PET\/CT, 18F-sodium fluoride PET\/CT and diffusion weighted-MRI at for the detection of bone metastases in biochemically recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2018;45(11):1884\u201397. https:\/\/doi.org\/10.1007\/s00259-018-4058-4 Epub 2018 Jun 6. PMID: 29876619.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"489_CR37","doi-asserted-by":"publisher","first-page":"101242","DOI":"10.1016\/j.tranon.2021.101242","volume":"15","author":"J Martinez","year":"2022","unstructured":"Martinez J, Subramanian K, Margolis D, O'Dwyer E, Osborne J, Jhanwar Y, et al. 68Ga-PSMA-HBED-CC PET\/MRI is superior to multiparametric magnetic resonance imaging in men with biochemical recurrent prostate cancer: a prospective single-institutional study. Transl Oncol. 2022;15(1):101242. https:\/\/doi.org\/10.1016\/j.tranon.2021.101242 Epub 2021 Oct 11. PMID: 34649151; PMCID: PMC8517922.","journal-title":"Transl Oncol"},{"issue":"3","key":"489_CR38","doi-asserted-by":"publisher","first-page":"781","DOI":"10.3390\/cancers14030781","volume":"14","author":"M Rasing","year":"2022","unstructured":"Rasing M, van Son M, Moerland M, de Keizer B, Wessels F, Jonges T, et al. Value of targeted biopsies and combined PSMA PET\/CT and mp-MRI imaging in locally recurrent prostate cancer after primary radiotherapy. Cancers (Basel). 2022;14(3):781. https:\/\/doi.org\/10.3390\/cancers14030781 PMID: 35159048; PMCID: PMC8834189.","journal-title":"Cancers (Basel)"},{"issue":"2","key":"489_CR39","first-page":"106","volume":"10","author":"M Radzina","year":"2020","unstructured":"Radzina M, Tirane M, Roznere L, Zemniece L, Dronka L, Kalnina M, et al. Accuracy of 68Ga-PSMA-11 PET\/CT and multiparametric MRI for the detection of local tumor and lymph node metastases in early biochemical recurrence of prostate cancer. Am J Nucl Med Mol Imaging. 2020;10(2):106\u201318 PMID: 32419979; PMCID: PMC7218697.","journal-title":"Am J Nucl Med Mol Imaging"},{"issue":"4","key":"489_CR40","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1055\/a-0828-8654","volume":"191","author":"L Umutlu","year":"2019","unstructured":"Umutlu L, Beyer T, Grueneisen JS, Rischpler C, Quick HH, Veit-Haibach P, et al. Vorstand der Interdisziplin\u00e4ren AG f\u00fcr Hybride Bildgebung in alphabetischer Reihenfolge; Vorstand der Deutschen R\u00f6ntgengesellschaft (DRG) und der Deutschen Gesellschaft f\u00fcr Nuklearmedizin (DGN) in alphabetischer Reihenfolge. Whole-body [18F]-FDG-PET\/MRI for oncology: a consensus recommendation. Rofo. 2019;191(4):289\u201397. https:\/\/doi.org\/10.1055\/a-0828-8654 Epub 2019 Feb 28. PMID: 30818411.","journal-title":"Rofo"},{"key":"489_CR41","doi-asserted-by":"publisher","unstructured":"Beuthien-Baumann B, Sachpekidis C, Gnirs R, Sedlaczek O. Adapting imaging protocols for PET-CT and PET-MRI for immunotherapy monitoring. Cancers. 2021. https:\/\/doi.org\/10.3390\/cancers13236019.","DOI":"10.3390\/cancers13236019"},{"issue":"8","key":"489_CR42","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s12149-019-01360-x","volume":"33","author":"U Yilmaz","year":"2019","unstructured":"Yilmaz U, Komek H, Can C, Altindag S. The role of (68Ga)PSMA I&T in biochemical recurrence after radical prostatectomy: detection rate and the correlation between the level of PSA, Gleason score, and the SUVmax. Ann Nucl Med. 2019;33(8):545\u201353. https:\/\/doi.org\/10.1007\/s12149-019-01360-x Epub 2019 May 8.","journal-title":"Ann Nucl Med"},{"issue":"9","key":"489_CR43","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s12149-017-1207-y","volume":"31","author":"Y Sanli","year":"2017","unstructured":"Sanli Y, Kuyumcu S, Sanli O, Buyukkaya F, \u0130riba\u015f A, Alcin G, et al. Relationships between serum PSA levels, Gleason scores and results of 68Ga-PSMAPET\/CT in patients with recurrent prostate cancer. Ann Nucl Med. 2017;31(9):709\u201317. https:\/\/doi.org\/10.1007\/s12149-017-1207-y Epub 2017 Sep 12.","journal-title":"Ann Nucl Med"},{"key":"489_CR44","doi-asserted-by":"publisher","first-page":"103718","DOI":"10.1155\/2014\/103718","volume":"2014","author":"A Piccardo","year":"2014","unstructured":"Piccardo A, Paparo F, Piccazzo R, Naseri M, Ricci P, Marziano A, et al. Value of fused 18F-Choline-PET\/MRI to evaluate prostate cancer relapse in patients showing biochemical recurrence after EBRT: preliminary results. Biomed Res Int. 2014;2014:103718. https:\/\/doi.org\/10.1155\/2014\/103718 Epub 2014 Apr 30. Erratum in: Biomed Res Int. 2016;2016:5047948. Picazzo, Riccardo [corrected to Piccazzo, Riccardo].","journal-title":"Biomed Res Int"}],"container-title":["Cancer Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40644-022-00489-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40644-022-00489-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40644-022-00489-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T23:22:12Z","timestamp":1663888932000},"score":1,"resource":{"primary":{"URL":"https:\/\/cancerimagingjournal.biomedcentral.com\/articles\/10.1186\/s40644-022-00489-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,22]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["489"],"URL":"https:\/\/doi.org\/10.1186\/s40644-022-00489-9","relation":{},"ISSN":["1470-7330"],"issn-type":[{"value":"1470-7330","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,22]]},"assertion":[{"value":"14 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional (S-225\/2021) and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.Informed consent was obtained from all participants enrolled in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Consent to publish has been received from all participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"53"}}